Halia Therapeutics receives FDA Fast Track designation for ofirnoflast in myelodysplastic syndromes
June 16, 2026 | 09:25
Halia Therapeutics has received FDA Fast Track designation for ofirnoflast in lower-risk myelodysplastic syndromes, following Phase 2 data showing durable transfusion independence and multilineage hematological improvement presented at EHA 2026.
Mobile Version